<DOC>
	<DOCNO>NCT01061515</DOCNO>
	<brief_summary>This study test escalate dos intraperitoneal ( IP ) oxaliplatin conjunction systemic bevacizumab capecitabine patient Peritoneal Carcinomatosis ( PC ) either appendiceal colorectal adenocarcinoma adequately cytoreduced undergone peritoneal scan demonstrate patency least one intraperitoneal port place time debulking .</brief_summary>
	<brief_title>Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine Bevacizumab Patients With Peritoneal Carcinomatosis From Appendiceal Colorectal Cancer</brief_title>
	<detailed_description>- To determine maximum tolerate dose IP oxaliplatin systemic intravenous bevacizumab oral capecitabine adequate surgical debulking peritoneal scan document function intraperitoneal port patient peritoneal carcinomatosis appendiceal colorectal etiology . - To assess safety tolerability repeat delayed intraperitoneal chemotherapy oxaliplatin systemic intravenous bevacizumab oral capecitabine adequate surgical debulking peritoneal scan document function intraperitoneal port patient peritoneal carcinomatosis appendiceal colorectal etiology . - To describe progression rate , progression-free survival overall survival patient treat regimen .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histological Diagnosis : Patients must histologically document peritoneal carcinomatosis either colorectal appendiceal adenocarcinoma . Prior Surgical Debulking : Patients must undergo debulking surgery peritonectomy allow least 4 week recover prior receive chemotherapy . Port Placement : Intraperitoneal port may place time separate surgical debulking . Provided patient allow least 4 week recover surgical debulking , additional recovery time require port placement . Active port : Patients must undergo peritoneal scan document least one work intraperitoneal port prior receive chemotherapy . Patients may receive prior chemotherapy . Age : Patients must ≥18 year age . Because dose toxicity data currently available use oxaliplatin patient &lt; 18 year age . Performance Status : ( Eastern cooperativeOncology Group ) ECOG 02 . Recovery Intercurrent Illness : Patients must recover uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia . Informed Consent : All patient must consent prior chemotherapy . The patient serious medical psychiatric illness would prevent either give informed consent receipt treatment . Hematological Status : absolute neutrophil count ≥1,500/mm³ platelet count ≥100,000/mm³ hemoglobin ≥8 g/dl . Hepatic function : Total bilirubin must &lt; 2X institutional upper limit normal ( ULN ) Transaminases ( SGOT and/or SGPT ) must ≤3X institutional upper limit normal ( ULN ) Alkaline phosphatase must ≤4X institutional upper limit normal ( ULN ) Renal Function : Patients must adequate renal function prior chemotherapy define serum creatinine ≤ 2.0 mg/dl creatinine clearance ≥60 ml.min/1.73 m² patient creatinine level 2.0 mg/dl . Pregnant breast feeding : For sexually active patient , use adequate contraception ( hormonal barrier method birth control ) require therapy , prior study entry , duration study participation . Nonpregnant status determine woman childbearing potential . Prior history hypersensitivity reaction oxaliplatin , bevacizumab , 5FU capecitabine . Gastrointestinal ailment may alter absorption oral medication ( i.e . bowel obstruction , shortgut syndrome ) . Patients receive antiretroviral therapy Highly Active Anti Retroviral Treatment ( HAART ) HIV infection exclude study possible pharmacokinetic interaction . Appropriate study undertake patient receive HAART therapy , indicate . Patients Grade 2 high peripheral neuropathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>